



SUBPOENA AD TESTIFICANDUM

1. TO

Paul Bisaro
President/CEO, Watson Pharmaceuticals, Inc.
c/o Steven C. Sunshine, Esq.
Skadden, Arps, Slate, Meagher & Flom, LLP
1440 New York Ave. NW, Washington, DC 20005

2. FROM

UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION

This subpoena requires you to appear and testify at the request of the Federal Trade Commission at a hearing [or deposition] in the proceeding described below (Item 6).

3. LOCATION OF HEARING

Federal Trade Commission
601 New Jersey Ave. NW
Washington, DC 20001
Rm 7100

4. YOUR APPEARANCE WILL BE BEFORE

Markus Meier

5. DATE AND TIME OF HEARING OR DEPOSITION

July 31, 2009 at 10:00am

6. SUBJECT OF INVESTIGATION

See attached resolution, File No. 0610182

7. RECORDS CUSTODIAN/DEPUTY RECORDS CUSTODIAN

Markus H. Meier, Records Custodian
Saralisa C. Brau, Deputy Records Custodian

8. COMMISSION COUNSEL

Saralisa Brau, Mark Woodward, Ellen Connelly, Alpa Gandhi

DATE ISSUED

7/27/09

COMMISSIONER'S SIGNATURE

GENERAL INSTRUCTIONS

The delivery of this subpoena to you by any method prescribed by the Commission's Rules of Practice is legal service and may subject you to a penalty imposed by law for failure to comply.

PETITION TO LIMIT OR QUASH

The Commission's Rules of Practice require that any petition to limit or quash this subpoena be filed within 20 days after service or, if the return date is less than 20 days after service, prior to the return date. The original and ten copies of the petition must be filed with the Secretary of the Federal Trade Commission. Send one copy to the Commission Counsel named in Item 8.

TRAVEL EXPENSES

Use the enclosed travel voucher to claim compensation to which you are entitled as a witness for the Commission. The completed travel voucher and this subpoena should be presented to Commission Counsel for payment. If you are permanently or temporarily living somewhere other than the address on this subpoena and it would require excessive travel for you to appear, you must get prior approval from Commission Counsel.

This subpoena does not require approval by OMB under the Paperwork Reduction Act of 1980.

FTC Form 68-A (rev. 10/93) The original was delivered to: Mr. Paul Bisaro
Watson Pharmaceuticals, Inc.
311 Bonnie Circle
Corona, California 92880

Copies were sent to counsel
identified under Item 1

RETURN OF SERVICE

I hereby certify that a duplicate original of the within subpoena was duly served: (check the method used)

in person.

by registered mail.

by leaving copy at principal office or place of business, to wit:

.....
.....
.....
.....

on the person named herein on:

.....
(Month, day, and year)

.....
(Name of person making service)

.....
(Official title)

UNITED STATES OF AMERICA
BEFORE THE FEDERAL TRADE COMMISSION

COMMISSIONERS: Deborah Platt Majoras, Chairman
Pamela Jones Harbour
Jon Leibowitz
William E. Kovacic
J. Thomas Rosch

RESOLUTION AUTHORIZING USE OF COMPULSORY
PROCESS IN A NONPUBLIC INVESTIGATION

File No. 0610182

Nature and Scope of Investigation:

To determine whether Cephalon, Inc., Teva Pharmaceutical Industries, Inc. (and its affiliate Teva Pharmaceuticals USA, Inc.), Barr Laboratories, Inc., Ranbaxy Laboratories, Inc., Mylan Pharmaceuticals, Inc., Carlsbad Technology, Inc., Watson Pharmaceuticals, Inc., or others have engaged in any unfair methods of competition that violate Section 5 of the Federal Trade Commission Act, 15 U.S.C. Sec. 45, as amended, by entering into agreements regarding any modafinil products.

The Federal Trade Commission hereby resolves and directs that any and all compulsory processes available to it be used in connection with this investigation.

Authority to Conduct Investigation:

Sections 6, 9, 10, and 20 of the Federal Trade Commission Act, 15 U.S.C. §§ 46, 49, 50, and 57b-1, as amended; FTC Procedures and Rules of Practice, 16 C.F.R. *et. seq.*, and supplements thereto.

By direction of the Commission.


Donald S. Clark
Secretary

ISSUED: August 30, 2006